Results 71 to 80 of about 63,667 (225)

The art of HIV elimination: past and present science [PDF]

, 2015
Introduction: Remarkable strides have been made in controlling the HIV epidemic, although not enough to achieve epidemic control. More recently, interest in biomedical HIV control approaches has increased, but substantial challenges with the HIV cascade ...
de Oliveira, T., Fisher, M., Lwuji, C.C., McGrath, N., Newell, M.-L., Newport, M., Pillay, D., Porter, K.   +7 more
core   +1 more source

Toward a Functional Cure for Chronic Hepatitis B: Current Landscape and Future Directions in Japan

Hepatology Research, EarlyView.
Hepatitis B is a viral liver infection that can become chronic, increasing the risk of developing liver cancer and liver failure. Because current treatments rarely cure these problems, researchers are now focusing on a functional cure in which the virus becomes undetectable in blood and stays that way, even after the treatment ends.
Yutaka Handa, Ethan Yichen Lee, Yasuhito Tanaka   +2 more
wiley   +1 more source

Tenofovir disoproxil fumarate induces peripheral neuropathy and alters inflammation and mitochondrial biogenesis in the brains of mice. [PDF]

, 2019
Mounting evidence suggests that antiretroviral therapy (ART) drugs may contribute to the prevalence of HIV-associated neurological dysfunction. The HIV envelope glycoprotein (gp120) is neurotoxic and has been linked to alterations in mitochondrial ...
Achim, Cristian L, Calcutt, Nigel A, Carson, Aliyah, Ellis, Ronald J, Fields, Jerel Adam, Frizzi, Katie, Han, May Madi, Lindsay, Charmaine, Murphy, Anne, Sambhwani, Shrey, Soontornniyomkij, Benchawanna, Swinton, Mary K   +11 more
core  

Depression and Oral FTC/TDF Pre-exposure Prophylaxis (PrEP) Among Men and Transgender Women Who Have Sex With Men (MSM/TGW). [PDF]

, 2016
We conducted a longitudinal and cross-sectional analysis of depressive symptomology in iPrEx, a randomized, placebo-controlled trial of daily, oral FTC/TDF HIV pre-exposure prophylaxis (PrEP) in men and transgender women who have sex with men. Depression-
Amico, K Rivet, Avelino-Silva, Vivian I, Burns, David, Chodacki, Piotr, Defechereux, Patricia A, Fernandez, Telmo, Glidden, David V, Grant, Robert M, iPrEx Study Team, Liu, Albert Y, Mayer, Kenneth H, McMahan, Vanessa M, Mehrotra, Megha, Vargas, Lorena   +13 more
core   +1 more source

Treatment durability, satisfaction and quality of life in virologically suppressed HIV‐1 people switching to doravirine: Results from the French study DoraVIH

HIV Medicine, EarlyView.
Abstract Objectives In Europe, most people with HIV‐1(PWH) achieve virologic suppression with effective and well‐tolerated antiretroviral therapies (ART). In this context, patient‐reported outcomes (PRO) are increasingly important for evaluating ART benefits.
Spire Bruno, Robineau Olivier, Pourcher Valérie, Loubet Paul, Palacios Christia, Jacomet Christine, Benachir Haydar, Mariot Philippe, Parienti Jean‐Jacques, Slama Laurence   +9 more
wiley   +1 more source

Urinary eicosanoid metabolites in HIV-infected women with central obesity switching to raltegravir: an analysis from the women, integrase, and fat accumulation trial. [PDF]

, 2014
Chronic inflammation is a hallmark of HIV infection. Eicosanoids reflect inflammation, oxidant stress, and vascular health and vary by sex and metabolic parameters. Raltegravir (RAL) is an HIV-1 integrase inhibitor that may have limited metabolic effects.
Boger, M Sean, Currier, Judith S, Hulgan, Todd, Lake, Jordan E, Liao, Diana H, Mangili, Alexandra, McComsey, Grace A, McCreath, Heather, Milne, Ginger L, Sanchez, Stephanie C, Walmsley, Sharon L, Wanke, Christine A   +11 more
core   +3 more sources

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART

HIV Medicine, EarlyView.
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson, Peter Dutey‐Magni, Carolina Herrera, Wolfgang Stöhr, Alejandro Arenas‐Pinto, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, John Tregoning, Sarah Fidler, François Raffi, Andrea Calcagno, Ab Babiker, Alan Winston   +13 more
wiley   +1 more source

Effect of tenofovir Administration And Withdrawl On The Kidney Tissues Of Adult Male Albino Rats And The Protective Role Of Vitamin E

SVU-International Journal of Veterinary Sciences, 2019
Tenofovir disoproxil fumarate is one of antiretroviral drugs used to treat chronic hepatitis B and HIV. In recent studies many Tenofovir problems were recorded; acute kidney injury (AKI), chronic kidney diseases (CKD) and Fanconi syndrome. Vitamin E is
Rasha M. Abd El-Fattah, Dorreia M. Zaghloul, Eman A. Abd Elrahim, Salwa M. Ouies   +3 more
doaj   +1 more source

Efficacy of dolutegravir/lamivudine in adults with HIV‐1 and isolated reactive hepatitis B core antibody: Insights from Phase 3/3b study results

HIV Medicine, EarlyView.
Abstract Objectives As two‐drug HIV‐1 antiretroviral therapy (ART) regimens become standard, data gaps remain concerning their safety and efficacy among people with isolated reactive hepatitis B core antibodies (anti‐HBc). Here, we assessed the safety and efficacy of dolutegravir/lamivudine (DTG/3TC) versus three‐ or four‐drug regimens (3DRs/4DRs ...
D. Fox, J. Slim, E. T. Overton, A. Doblado‐Maldonado, P. Jeffery, R. A. Grove, S. D. Advani, R. Borsi, C. M. Parry, M. Underwood, B. Jones   +10 more
wiley   +1 more source